Announcements

Maintaining America's Leadership in Biomedical Innovation: FDA's Role in Advancing U.S. Drug Development Written Testimony
Maintaining America's Leadership in Biomedical Innovation: FDA's Role in Advancing U.S. Drug Development Written Testimony
Read More
Call for Nominations for the 2026 Innovations in Regulatory Science & Policy Awards
The Reagan-Udall Foundation for the FDA invites nominations for its annual Innovations in Regulatory Science & Policy Awards.
Read More
Reagan-Udall Foundation for the FDA Announces New Board Chair; Welcomes New Board Member
(February 6, 2026) The Reagan-Udall Foundation for the FDA (Foundation) has appointed Adrian F. Hernandez, MD, MHS, as Chair of its Board of Directors. Dr. Hernandez, who has served on the Board since 2019, is a cardiologist and the Vice Dean for…
Read More
More Announcements

Coverage

FDA: Psychedelic Drugs
FDA is supporting the development of psychedelic drugs, including new treatments for serious mental health conditions.
Read More
Regulatory Affairs Professionals Society: This Week at FDA: WH reviewing candidates for FDA boss, a pause on posting CRLs, and more
The Reagan-Udall Foundation for the FDA and FDA are hosting a hybrid meeting on 5 August to discuss selection criteria and prioritization when considering repurposing drugs for new indications or new populations.
Read More
Pharma Now: FDA and Reagan-Udall Foundation Convene August 2026 Meeting to Advance Drug Repurposing Selection Criteria
Manufacturing capacity already validated under 21 CFR Part 211 and existing safety dossiers could become strategic assets as the Reagan-Udall Foundation for the FDA convenes a hybrid public meeting on August 5, 2026, to shape how repurposing candidates…
Read More
More Coverage